AUSTIN, TX & MENLO PARK, CA – [June 26, 2025] – Everlywell today announced a collaboration with GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, to expand access to its Galleri® multi-cancer early detection test. Everlywell, a digital health company pioneering the next generation of biomarker intelligence, now offers the Galleri test for request directly on everlywell.com via prescription only.
This year, an estimated 2 million people in the U.S. will be diagnosed with cancer and more than 1,700 will die from it each day.1 Early detection can save lives—with a five-year survival rate of 89% when caught early, compared to just 21% when found late.2 Still, 7 in 10 adults are behind on at least one routine cancer screening.3
“We can now treat cancer far more effectively, but we cannot treat what we have not found. While doctors can screen today for five single cancers, nearly 70% of deaths are caused by cancers with no recommended screening tests. This is because we are finding most cancers too late,” said Josh Ofman, MD, MSHS, President at GRAIL. “Adding a multi-cancer early detection test, like the Galleri test, to recommended cancer screenings can be a game-changer to finding cancers before symptoms appear, when they are often at earlier stages, providing more treatment options, and less costly to individuals, their families and society. By collaborating with Everlywell, we are making this breakthrough technology more accessible to support earlier detection.”
Cancers growing in the body shed DNA into the bloodstream. The Galleri test screens these DNA fragments for a cancer signal shared by more than 50 types of cancer, including many of the deadliest, often before they become symptomatic. The Galleri test can also help predict the origin of the cancer signal to help guide further diagnostic evaluation. The Galleri test is prescription only, recommended for adults with an elevated risk for cancer, such as those aged 50 or older, and is to be used in addition to recommended cancer screenings.
“For nearly 60 million people, Everlywell has been reshaping how and where healthcare happens by combining AI-powered technology with human insight to deliver actionable health answers,” said Gabe Gaviola, MD, MPH, Senior Medical Director at Everlywell. “Collaborating with GRAIL to offer the Galleri test on our platform brings a groundbreaking innovation in cancer detection directly to millions of people. As a company that has transformed how people access care for nearly a decade, we know innovation only matters when it’s accessible—and access is what changes lives. We’re empowering people with answers when it matters most.”
Everlywell and GRAIL’s collaboration underscores their shared commitment to transform the way people approach preventive healthcare, increasing access to cutting-edge, population-based cancer screening.
About Everlywell
Everlywell is a digital health company pioneering the next generation of biomarker intelligence—combining AI-powered technology with human insight to deliver personalized, actionable health answers.
Over the past decade, Everlywell has delivered close to 1 billion personalized health insights, transforming care for 60 million people. In 2024 alone, an estimated 1 in 86 U.S. households received an Everlywell test, solidifying our spot as the #1 at-home testing brand in the country. Fueled by AI and built for scale, we’re breaking down barriers, closing care gaps, and unlocking a more connected healthcare experience that is smarter, faster, and more personalized. Learn more at everlywell.com.
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
References
- American Cancer Society. Cancer Facts & Figures 2025. Accessed May 19, 2025.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015. “Early/Localized” includes invasive localized tumors that have not spread beyond organ of origin. “Late/Distant Metastases” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body. Data on file GA-2021-004.
- U.S. adults are still behind on routine cancer screenings—but reasons why vary by race. Prevent Cancer Foundation. Accessed on May 19, 2025.
Contacts
Jensen Cannon, Everlywell
[email protected]